List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/5225669/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Early expansion of CD38+ICOS+ GC Tfh in draining lymph nodes during influenza vaccination immune response. IScience, 2022, 25, 103656.	4.1	8
2	Altered Immune Reconstitution in Allogeneic Stem Cell Transplant Recipients With Human Immunodeficiency Virus (HIV). Clinical Infectious Diseases, 2021, 72, 1141-1146.	5.8	2
3	CD73+ CD127high Long-Term Memory CD4 T Cells Are Highly Proliferative in Response to Recall Antigens and Are Early Targets in HIV-1 Infection. International Journal of Molecular Sciences, 2021, 22, 912.	4.1	2
4	The Role of ZEB2 in Human CD8 T Lymphocytes: Clinical and Cellular Immune Profiling in Mowat–Wilson Syndrome. International Journal of Molecular Sciences, 2021, 22, 5324.	4.1	4
5	HIV-1 viral blips are associated with repeated and increasingly high levels of cell-associated HIV-1 RNA transcriptional activity. Aids, 2021, 35, 2095-2103.	2.2	12
6	Long-term and short-term immunity to SARS-CoV-2: why it matters. Microbiology Australia, 2021, 42, 34.	0.4	0
7	Editorial: Infectious Agent-Induced Chronic Immune Activation: Causes, Phenotypes, and Consequences. Frontiers in Immunology, 2021, 12, 740556.	4.8	1
8	Circulating glutenâ€specific, but not CMVâ€specific, CD39 + regulatory T cells have an oligoclonal TCR repertoire. Clinical and Translational Immunology, 2020, 9, e1096.	3.8	7
9	Mapping the extent of heterogeneity of human CCR5+ CD4+ T cells in peripheral blood and lymph nodes. Aids, 2020, 34, 833-848.	2.2	17
10	Possible clearance of transfusion-acquired nef/LTR-deleted attenuated HIV-1 infection by an elite controller with CCR5 Δ32 heterozygous and HLA-B57 genotype. Journal of Virus Eradication, 2019, 5, 73-83.	0.5	13
11	Intersection of immune checkpoints and CD8+ T cell noncytolytic suppression of HIV-1 infection. Aids, 2019, 33, 581-583.	2.2	0
12	HIV latency can be established in proliferating and nonproliferating resting CD4+ T cells in vitro. Aids, 2019, 33, 199-209.	2.2	8
13	HIV-1 DNA Is Maintained in Antigen-Specific CD4+ T Cell Subsets in Patients on Long-Term Antiretroviral Therapy Regardless of Recurrent Antigen Exposure. AIDS Research and Human Retroviruses, 2019, 35, 112-120.	1.1	16
14	Possible clearance of transfusion-acquired /LTR-deleted attenuated HIV-1 infection by an elite controller with CCR5 Î"32 heterozygous and HLA-B57 genotype. Journal of Virus Eradication, 2019, 5, 73-83.	0.5	5
15	Memory B cells are reactivated in subcapsular proliferative foci of lymph nodes. Nature Communications, 2018, 9, 3372.	12.8	88
16	Impact of Allogeneic Hematopoietic Stem Cell Transplantation on the HIV Reservoir and Immune Response in 3 HIV-Infected Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 328-337.	2.1	32
17	Singleâ€cell profiling of lineage determining transcription factors in antigenâ€specific CD4 + T cells reveals unexpected complexity in recall responses during immune reconstitution. Immunology and Cell Biology, 2017, 95, 640-646.	2.3	6
18	Quantification of Residual Germinal Center Activity and HIV-1 DNA and RNA Levels Using Fine Needle Biopsies of Lymph Nodes During Antiretroviral Therapy. AIDS Research and Human Retroviruses, 2017, 33, 648-657.	1.1	32

JOHN JAMES ZAUNDERS

#	Article	IF	CITATIONS
19	Cytotoxic CD4 T Cells—Friend or Foe during Viral Infection?. Frontiers in Immunology, 2017, 8, 19.	4.8	177
20	HIV-1 and SIV Predominantly Use CCR5 Expressed on a Precursor Population to Establish Infection in T Follicular Helper Cells. Frontiers in Immunology, 2017, 8, 376.	4.8	26
21	Divergent Expression of CXCR5 and CCR5 on CD4+ T Cells and the Paradoxical Accumulation of T Follicular Helper Cells during HIV Infection. Frontiers in Immunology, 2017, 8, 495.	4.8	11
22	Editorial: Cytotoxic CD4+ T Cells in Viral Infections. Frontiers in Immunology, 2017, 8, 1729.	4.8	9
23	HIV dynamics linked to memory CD4+ T cell homeostasis. PLoS ONE, 2017, 12, e0186101.	2.5	11
24	CD4+ T Follicular Helper and IgA+ B Cell Numbers in Gut Biopsies from HIV-Infected Subjects on Antiretroviral Therapy Are Similar to HIV-Uninfected Individuals. Frontiers in Immunology, 2016, 7, 438.	4.8	13
25	Nuclear PKC-Î, facilitates rapid transcriptional responses in human memory CD4+ T cells <i>via</i> p65 and H2B phosphorylation. Journal of Cell Science, 2016, 129, 2448-61.	2.0	11
26	Computationally efficient multidimensional analysis of complex flow cytometry data using second order polynomial histograms. Cytometry Part A: the Journal of the International Society for Analytical Cytology, 2016, 89, 44-58.	1.5	10
27	Hepatitis Câ€specific effector and regulatory <scp>CD</scp> 4 Tâ€cell responses are associated with the outcomes of primary infection. Journal of Viral Hepatitis, 2016, 23, 985-993.	2.0	13
28	Comment on "A Cytokine-Independent Approach To Identify Antigen-Specific Human Germinal Center T Follicular Helper Cells and Rare Antigen-Specific CD4+ T Cells in Blood― Journal of Immunology, 2016, 197, 2557-2558.	0.8	3
29	Cellular comparison of sinus mucosa vs polyp tissue from a single sinus cavity in chronic rhinosinusitis. International Forum of Allergy and Rhinology, 2015, 5, 14-27.	2.8	29
30	Detecting Antigen-Specific T Cell Responses: From Bulk Populations to Single Cells. International Journal of Molecular Sciences, 2015, 16, 18878-18893.	4.1	28
31	Human Papillomavirus 16–Specific T-Cell Responses and Spontaneous Regression of Anal High-Grade Squamous Intraepithelial Lesions. Journal of Infectious Diseases, 2015, 211, 405-415.	4.0	29
32	Early antiretroviral therapy with raltegravir generates sustained reductions in HIV reservoirs but not lower T-cell activation levels. Aids, 2015, 29, 911-919.	2.2	37
33	Group 2 innate lymphoid cells ( <scp>ILC</scp> 2s) are increased in chronic rhinosinusitis with nasal polyps or eosinophilia. Clinical and Experimental Allergy, 2015, 45, 394-403.	2.9	136
34	HIV-Infected Spleens Present Altered Follicular Helper T Cell (Tfh) Subsets and Skewed B Cell Maturation. PLoS ONE, 2015, 10, e0140978.	2.5	49
35	Ratios of effector to central memory antigenâ€specific CD4 <sup>+</sup> T cells vary with antigen exposure in HIV+ patients. Immunology and Cell Biology, 2014, 92, 384-388.	2.3	10
36	HIV DNA Subspecies Persist in both Activated and Resting Memory CD4 <sup>+</sup> T Cells during Antiretroviral Therapy. Journal of Virology, 2014, 88, 3516-3526.	3.4	76

#	Article	IF	CITATIONS
37	Human antigenâ€specific CD4 <sup>+</sup> CD25 <sup>+</sup> CD134 <sup>+</sup> CD39 <sup>+</sup> TÂcells are enriched for regulatory TÂcells and comprise a substantial proportion of recall responses. European Journal of Immunology, 2014, 44, 1644-1661.	2.9	58
38	Exploiting differential expression of the IL-7 receptor on memory T cells to modulate immune responses. Cytokine and Growth Factor Reviews, 2014, 25, 391-401.	7.2	31
39	Incomplete restoration of Mycobacterium tuberculosis-specific-CD4 T cell responses despite antiretroviral therapy. Journal of Infection, 2014, 68, 344-354.	3.3	15
40	CD4 T Cells Mediate Both Positive and Negative Regulation of the Immune Response to HIV Infection: Complex Role of T Follicular Helper Cells and Regulatory T Cells in Pathogenesis. Frontiers in Immunology, 2014, 5, 681.	4.8	29
41	Serial study of lymph node cell subsets using fine needle aspiration in pigtail macaques. Journal of Immunological Methods, 2013, 394, 73-83.	1.4	22
42	HIV integrase and the swan song of the CD4 T cells?. Retrovirology, 2013, 10, 149.	2.0	6
43	Simian Immunodeficiency Virus Infects Follicular Helper CD4 T Cells in Lymphoid Tissues during Pathogenic Infection of Pigtail Macaques. Journal of Virology, 2013, 87, 3760-3773.	3.4	94
44	Innate and Adaptive Immunity in Long-Term Non-Progression in HIV Disease. Frontiers in Immunology, 2013, 4, 95.	4.8	45
45	The micro <scp>RNA</scp> â€9/ <scp>B</scp> â€lymphocyteâ€induced maturation proteinâ€1/ <scp>IL</scp> â€2 differentially regulated in progressive <scp>HIV</scp> infection. European Journal of Immunology, 2013, 43, 510-520.	axis is 2.9	48
46	The Majority of HIV Type 1 DNA in Circulating CD4+T Lymphocytes Is Present in Non-Gut-Homing Resting Memory CD4+T Cells. AIDS Research and Human Retroviruses, 2013, 29, 1330-1339.	1.1	18
47	Short Communication: HIV Blips While on Antiretroviral Therapy Can Indicate Consistently Detectable Viral Levels Due to Assay Underreporting. AIDS Research and Human Retroviruses, 2013, 29, 1621-1625.	1.1	7
48	Characterization of Transcription Factor Phenotypes within Antigen-Specific CD4+ T Cells Using Qualitative Multiplex Single-Cell RT-PCR. PLoS ONE, 2013, 8, e74946.	2.5	16
49	Restoration of CMV-Specific-CD4 T Cells with ART Occurs Early and Is Greater in Those with More Advanced Immunodeficiency. PLoS ONE, 2013, 8, e77479.	2.5	17
50	Integrated HIV DNA accumulates prior to treatment while episomal HIV DNA records ongoing transmission afterwards. Aids, 2012, 26, 543-550.	2.2	62
51	T-lymphocyte perturbation following large-scale apheresis and hematopoietic stem cell transplantation in HIV-infected individuals. Clinical Immunology, 2012, 144, 159-171.	3.2	11
52	Progressive Activation of CD127+132â^ Recent Thymic Emigrants into Terminally Differentiated CD127â^ 132+ T-Cells in HIV-1 Infection. PLoS ONE, 2012, 7, e31148.	2.5	7
53	A novel assay detecting recall response to MycobacteriumÂtuberculosis: Comparison with existing assays. Tuberculosis, 2012, 92, 321-327.	1.9	25
54	A novel assay for detection of hepatitis C virus-specific effector CD4+ T cells via co-expression of CD25 and CD134. Journal of Immunological Methods, 2012, 375, 148-158.	1.4	29

#	Article	IF	CITATIONS
55	HIV disease progression despite suppression of viral replication is associated with exhaustion of lymphopoiesis. Blood, 2011, 117, 5142-5151.	1.4	140
56	Impact of treatment with raltegravir during primary or chronic HIV infection on RNA decay characteristics and the HIV viral reservoir. Aids, 2011, 25, 2069-2078.	2.2	69
57	The Sydney Blood Bank Cohort: implications for viral fitness as a cause of elite control. Current Opinion in HIV and AIDS, 2011, 6, 151-156.	3.8	40
58	Persistent Survival of Prevalent Clonotypes within an Immunodominant HIV Gag-Specific CD8+ T Cell Response. Journal of Immunology, 2011, 186, 359-371.	0.8	40
59	HIV/SIV Infection Primes Monocytes and Dendritic Cells for Apoptosis. PLoS Pathogens, 2011, 7, e1002087.	4.7	56
60	A Novel Chemokine-Receptor-5 (CCR5) Blocker, SCH532706, Has Differential Effects on CCR5+CD4+and CCR5+CD8+T Cell Numbers in Chronic HIV Infection. AIDS Research and Human Retroviruses, 2010, 26, 653-661.	1.1	14
61	AIDS Progression Is Associated with the Emergence of IL-17–Producing Cells Early After Simian Immunodeficiency Virus Infection. Journal of Immunology, 2010, 184, 984-992.	0.8	53
62	Nonpathogenesis of Simian Immunodeficiency Virus Infection Is Associated with Reduced Inflammation and Recruitment of Plasmacytoid Dendritic Cells to Lymph Nodes, Not to Lack of an Interferon Type I Response, during the Acute Phase. Journal of Virology, 2010, 84, 1838-1846.	3.4	58
63	IL-7 receptor is expressed on adult pre-B-cell acute lymphoblastic leukemia and other B-cell derived neoplasms and correlates with expression of proliferation and survival markers. Cytokine, 2010, 50, 58-68.	3.2	38
64	Cytokines and theÂpathogenesis ofÂHIV infection. European Cytokine Network, 2010, 21, 195-6.	2.0	2
65	IL-17 andÂHIV pathogenesis. European Cytokine Network, 2010, 21, 222-5.	2.0	1
66	High Levels of Human Antigen-Specific CD4+ T Cells in Peripheral Blood Revealed by Stimulated Coexpression of CD25 and CD134 (OX40). Journal of Immunology, 2009, 183, 2827-2836.	0.8	153
67	A culture amplified multi-parametric intracellular cytokine assay (CAMP-ICC) for enhanced detection of antigen specific T-cell responses. Journal of Immunological Methods, 2009, 345, 1-16.	1.4	18
68	Proliferation of weakly suppressive regulatory CD4 <sup>+</sup> T cells is associated with overâ€active CD4 <sup>+</sup> Tâ€cell responses in HIVâ€positive patients with mycobacterial immune restoration disease. European Journal of Immunology, 2009, 39, 391-403.	2.9	111
69	Does the presence of anti-HIV miRNAs in monocytes explain their resistance to HIV-1 infection?. Blood, 2009, 113, 5029-5030.	1.4	22
70	Safety, immunogenicity and efficacy of peptideâ€pulsed cellular immunotherapy in macaques. Journal of Medical Primatology, 2008, 37, 69-78.	0.6	12
71	Mechanisms of HIV non-progression; robust and sustained CD4+ T-cell proliferative responses to p24 antigen correlate with control of viraemia and lack of disease progression after long-term transfusion-acquired HIV-1 infection. Retrovirology, 2008, 5, 112.	2.0	68
72	Virologic Determinants of Success After Structured Treatment Interruptions of Antiretrovirals in Acute HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2008, 47, 140-147.	2.1	38

#	Article	IF	CITATIONS
73	Human Mesenchymal Stem Cells Constitutively Express Chemokines and Chemokine Receptors That Can Be Upregulated by Cytokines, IFN-β, and Copaxone. Journal of Interferon and Cytokine Research, 2007, 27, 53-64.	1.2	105
74	Pathogenicity and immunogenicity of attenuated, nef-deleted HIV-1 strains in vivo. Retrovirology, 2007, 4, 66.	2.0	60
75	Antibody microarray analysis of cell surface antigens on CD4+ and CD8+ T cells from HIV+ individuals correlates with disease stages. Retrovirology, 2007, 4, 83.	2.0	20
76	Upregulation of CTLA-4 by HIV-specific CD4+ T cells correlates with disease progression and defines a reversible immune dysfunction. Nature Immunology, 2007, 8, 1246-1254.	14.5	485
77	Su.3. Generation In Vitro of T Lineage Cells from Human Adult Haematopoietic Stem Cells. Clinical Immunology, 2006, 119, s160.	3.2	0
78	Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. Journal of Experimental Medicine, 2006, 203, 1693-1700.	8.5	1,354
79	The IL-7/IL-7 Receptor Axis: Understanding its Central Role in T-Cell Homeostasis and the Challenges Facing its Utilization as a Novel Therapy. Current Drug Targets, 2006, 7, 1571-1582.	2.1	58
80	Decimated or missing in action: CD4+ T cells as targets and effectors in the pathogenesis of primary HIV infection. Current HIV/AIDS Reports, 2006, 3, 5-12.	3.1	22
81	The Role of Hydroxyurea in Enhancing the Virologic Control Achieved Through Structured Treatment Interruption in Primary HIV Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 42, 192-202.	2.1	26
82	CD127 + CCR5 + CD38 +++ CD4 + Th1 Effector Cells Are an Early Component of the Primary Immune Response to Vaccinia Virus and Precede Development of Interleukin-2 + Memory CD4 + T Cells. Journal of Virology, 2006, 80, 10151-10161.	3.4	47
83	Increased Plasma Interleukinâ€7 Level Correlates with Decreased CD127 and Increased CD132 Extracellular Expression on T Cell Subsets in Patients with HIVâ€1 Infection. Journal of Infectious Diseases, 2006, 193, 505-514.	4.0	108
84	Infection of CD127 + (Interleukin-7 Receptor + ) CD4 + Cells and Overexpression of CTLA-4 Are Linked to Loss of Antigen-Specific CD4 T Cells during Primary Human Immunodeficiency Virus Type 1 Infection. Journal of Virology, 2006, 80, 10162-10172.	3.4	84
85	Early proliferation of CCR5+ CD38+++ antigen-specific CD4+ Th1 effector cells during primary HIV-1 infection. Blood, 2005, 106, 1660-1667.	1.4	77
86	A New Variant Cytotoxic T Lymphocyte Escape Mutation in HLA-B27-Positive Individuals Infected with HIV Type 1. AIDS Research and Human Retroviruses, 2005, 21, 395-397.	1.1	34
87	CD8+ T Cell Dynamics during Primary Simian Immunodeficiency Virus Infection in Macaques: Relationship of Effector Cell Differentiation with the Extent of Viral Replication. Journal of Immunology, 2005, 174, 6898-6908.	0.8	36
88	Prolonged transcriptional silencing and CpG methylation induced by siRNAs targeted to the HIV-1 promoter region. Journal of Rnai and Gene Silencing, 2005, 1, 66-78.	1.2	76
89	Increased Natural Killer Cell Activity in Viremic HIV-1 Infection. Journal of Immunology, 2004, 173, 5305-5311.	0.8	128
90	Phase I clinical trial of a human idiotypic p53 vaccine in patients with advanced malignancy. Annals of Oncology, 2004, 15, 324-329.	1.2	14

#	Article	IF	CITATIONS
91	Identification of circulating antigen-specific CD4+ T lymphocytes with a CCR5+, cytotoxic phenotype in an HIV-1 long-term nonprogressor and in CMV infection. Blood, 2004, 103, 2238-2247.	1.4	160
92	HIV-1–specific cytotoxicity is preferentially mediated by a subset of CD8+ T cells producing both interferon-γ and tumor necrosis factor–α. Blood, 2004, 104, 487-494.	1.4	124
93	First demonstration of a lack of viral sequence evolution in a nonprogressor, defining replication-incompetent HIV-1 infection. Virology, 2003, 312, 135-150.	2.4	63
94	Naive T cells are maintained by thymic output in early ages but by proliferation without phenotypic change after age twenty. Immunology and Cell Biology, 2003, 81, 487-495.	2.3	99
95	Development of real-time detection direct test for hepatitis B virus and comparison with two commercial tests using the WHO international standard. Journal of Gastroenterology and Hepatology (Australia), 2003, 18, 1264-1271.	2.8	19
96	Greater Reversal of CD4+ Cell Abnormalities and Viral Load Reduction after Initiation of Antiretroviral Therapy with Zidovudine, Lamivudine, and Nelfinavir before Complete HIV Type 1 Seroconversion. AIDS Research and Human Retroviruses, 2003, 19, 189-199.	1.1	12
97	Polyclonal Proliferation and Apoptosis of CCR5+T Lymphocytes during Primary Human Immunodeficiency Virus Type 1 Infection: Regulation by Interleukin (IL)–2, ILâ€15, and Bclâ€2. Journal of Infectious Diseases, 2003, 187, 1735-1747.	4.0	63
98	Macrophage inhibitory cytokine 1 reduces cell adhesion and induces apoptosis in prostate cancer cells. Cancer Research, 2003, 63, 5034-40.	0.9	136
99	Characterization of CD4+ CTLs Ex Vivo. Journal of Immunology, 2002, 168, 5954-5958.	0.8	491
100	Dynamics of T Cells and TCR Excision Circles Differ After Treatment of Acute and Chronic HIV Infection. Journal of Immunology, 2002, 169, 4657-4666.	0.8	49
101	Parallel decline of CD8+/CD38++ T cells and viraemia in response to quadruple highly active antiretroviral therapy in primary HIV infection. Aids, 2002, 16, 589-596.	2.2	73
102	The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy. Aids, 2002, 16, 359-367.	2.2	157
103	STI and beyond: the prospects of boosting anti-HIV immune responses. Trends in Immunology, 2002, 23, 456-460.	6.8	22
104	Cell turnover and cell tropism in HIV-1 infection. Trends in Microbiology, 2002, 10, 275-278.	7.7	29
105	Characterization of the phenotypic and lymphokine profile associated with strong CD8 + anti-HIV-1 suppressor activity (CASA). Clinical and Experimental Immunology, 2002, 127, 145-150.	2.6	7
106	Comprehensive Analyses of a Unique HIV-1-Infected Nonprogressor Reveal a Complex Association of Immunobiological Mechanisms in the Context of Replication-Incompetent Infection. Virology, 2002, 304, 246-264.	2.4	41
107	Relative Significance of Different Pathways of Immune Reconstitution in HIV Type 1 Infection as Estimated by Mathematical Modeling. AIDS Research and Human Retroviruses, 2001, 17, 147-159.	1.1	20
108	An examination of signs of disease progression in survivors of the Sydney Blood Bank Cohort (SBBC). Journal of Clinical Virology, 2001, 22, 263-270.	3.1	68

#	Article	IF	CITATIONS
109	Increased Turnover of CCR5+and Redistribution of CCR5â^CD4 T Lymphocytes during Primary Human Immunodeficiency Virus Type 1 Infection. Journal of Infectious Diseases, 2001, 183, 736-743.	4.0	42
110	Novel Deletion of HIV Type 1 Reverse Transcriptase Residue 69 Conferring Selective High-Level Resistance to Nevirapine. AIDS Research and Human Retroviruses, 2001, 17, 1293-1296.	1.1	10
111	Impact of HIV Type 1 Protease, Reverse Transcriptase, Cleavage Site, and p6 Mutations on the Virological Response to Quadruple Therapy with Saquinavir, Ritonavir, and Two Nucleoside Analogs. AIDS Research and Human Retroviruses, 2001, 17, 487-497.	1.1	37
112	HIV induces lymphocyte apoptosis by a p53â€initiated, mitochondrialâ€mediated mechanism. FASEB Journal, 2001, 15, 5-6.	0.5	114
113	Long-term immunological response in HIV-1-infected subjects receiving potent antiretroviral therapy. Aids, 2000, 14, 959-969.	2.2	85
114	Rapid restoration of CD4 T cell subsets in subjects receiving antiretroviral therapy during primary HIV-1 infection. Aids, 2000, 14, 2643-2651.	2.2	88
115	Reply. Journal of Infectious Diseases, 2000, 181, 1519-1520.	4.0	1
116	Potent Antiretroviral Therapy of Primary Human Immunodeficiency Virus Type 1 (HIVâ€1) Infection: Partial Normalization of T Lymphocyte Subsets and Limited Reduction of HIVâ€1 DNA Despite Clearance of Plasma Viremia. Journal of Infectious Diseases, 1999, 180, 320-329.	4.0	110
117	Immune reconstitution in HIV-1 infected subjects treated with potent antiretroviral therapy. Sexually Transmitted Infections, 1999, 75, 218-224.	1.9	28
118	Phenotypic Analysis of CD8+ T Lymphocytes in a Cohort of HIV Type 1-Infected Patients Treated with Saquinavir, Ritonavir, and Two Nucleoside Analogs for 1 Year, and Association with Plasma HIV Type 1 RNA. AIDS Research and Human Retroviruses, 1999, 15, 963-972.	1.1	21
119	Effect of Long-Term Infection with nef-Defective Attenuated HIV Type 1 on CD4+ and CD8+ T Lymphocytes: Increased CD45RO+ CD4+ T Lymphocytes and Limited Activation of CD8+ T Lymphocytes. AIDS Research and Human Retroviruses, 1999, 15, 1519-1527.	1.1	28
120	Impact of Early HIV-1 RNA and T-Lymphocyte Dynamics During Primary HIV-1 Infection on the Subsequent Course of HIV-1 RNA Levels and CD4+ T-Lymphocyte Counts in the First Year of HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 1999, 22, 437.	2.1	25
121	Impact of Early HIV-1 RNA and T-Lymphocyte Dynamics During Primary HIV-1 Infection on the Subsequent Course of HIV-1 RNA Levels and CD4+ T-Lymphocyte Counts in the First Year of HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 1999, 22, 437.	2.1	19
122	Composition and function of peripheral blood stem and progenitor cell harvests from patients with severe active rheumatoid arthritis. British Journal of Haematology, 1998, 103, 601-609.	2.5	21
123	Patterns of Viral Dynamics during Primary Human Immunodeficiency Virus Type 1 Infection. Journal of Infectious Diseases, 1998, 178, 1812-1815.	4.0	85
124	Primary HIV-1 Infection: A Review of Clinical Manifestations, Immunologic and Virologic Changes. AIDS Patient Care and STDs, 1998, 12, 759-767.	2.5	19
125	Alterations in the Immune Response of Human Immunodeficiency Virus (HIV)-Infected Subjects Treated with an HIV-Specific Protease Inhibitor, Ritonavir. Journal of Infectious Diseases, 1996, 173, 321-329.	4.0	332
126	Effects of primary HIV-1 infection on subsets of CD4+ and CD8+ T lymphocytes. Aids, 1995, 9, 561-566.	2.2	68

#	ARTICLE	IF	CITATIONS
127	Radiation Pneumonitis: A Possible Lymphocyte-mediated Hypersensitivity Reaction. Annals of Internal Medicine, 1993, 118, 696.	3.9	170
128	A Monoclonal Antibody-Based Radioimmunoassay for the in vitro Production of IgE by Lymphocyte Cultures. International Archives of Allergy and Immunology, 1985, 78, 1-8.	2.1	6
129	Immunoregulation in Juvenile Chronic Arthritis. International Archives of Allergy and Immunology, 1984, 75, 196-202.	2.1	3
130	Characterization of antigens recognized by natural killer cells in cell-culture supernatants. British Journal of Cancer, 1981, 43, 5-12.	6.4	11